Study of Aripiprazole to Treat Children and Adolescents With Autism (PAIRS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00619190|
Recruitment Status : Completed
First Posted : February 20, 2008
Results First Posted : March 26, 2014
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Autistic Disorder Asperger Syndrome Autism Spectrum Disorder||Drug: aripiprazole||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Study of Aripiprazole in Children and Adolescents With Autism Spectrum Disorders|
|Study Start Date :||January 2006|
|Primary Completion Date :||June 2012|
|Study Completion Date :||June 2012|
Experimental: open aripipraprazole
Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
Other Name: Abilify
No Intervention: no medication control
group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
- Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks [ Time Frame: Baseline to 12 weeks ]The Aberrant Behavior Checklist (ABC) is a caregiver rated questionnaire for assessing problem behaviors of children over the past week relative to typically developing children of the same age. Problem behaviors are rated on a categorical scale between 0 not at all a problem and 3 problem is severe in degree. Raters are instructed to consider both the severity and the frequency of the behavior in determining how severe a problem the behavior is. Thus, if a given behavior occurs more often than in other children of the same age and sex, scores greater than or equal to 1 are warranted. The total score can range from a minimum of 0 (no problem behaviors) to a maximum of 174, higher the number the worse the symptoms.The irritability subscale consists of 15 items with a minimal score of 0 - no irritability problems to 45 - all irritability items rated as severe. A rating of 18 or more on the irritability subscale is considered clinically significant.
- Clinical Global Impressions Scale - Severity Score (CGI-S) [ Time Frame: Baseline to 12 weeks ]
One of the most widely used of clinician assessment tools in psychiatry, the CGI is an observer-rated scale that measures illness severity (CGI-S).
The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (among the most severely ill patients).
- Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks [ Time Frame: Baseline to 12 weeks ]The Aberrant Behavior Checklist lethargy/social withdrawal subscale (ABC-SW) is the sum of ratings from 0 - not a problem at all to 3 - problem is severe in degree on 16 items within the Aberrant Behavior checklist (also described in the primary outcome measure section above). Scores can range from 0 to 48, with higher scores indicating more severe problems. The period for the rating is one week and the reference group is typically developing children of the same age and gender as the participant. Both frequency of the behaviors and severity of the problems related to them are considered. High ratings on these items reflect lack of response and interaction with other people in the child's environment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00619190
|United States, North Carolina|
|University of North Carolina, Department of Psychiatry|
|Chapel Hill, North Carolina, United States, 27514|
|Principal Investigator:||Linmarie Sikich, MD||University of North Carolina, Department of Psychiatry|